Loading...
•
Dec 31, 2020
PMV Pharma Q4 2020 Earnings Report
PMV Pharma's financial position was strengthened by increase in cash and cash equivalents. Phase 1/2 study of PC14586 was initiated and Fast Track designation was granted by FDA.
Key Takeaways
PMV Pharmaceuticals reported its Q4 and full year 2020 financial results, highlighting the initiation of Phase 1/2 study of PC14586 and a strengthened financial position with $361.4 million in cash, cash equivalents, and marketable securities.
Initiated Phase 1/2 study of PC14586 in patients with advanced solid tumors that have a p53 Y220C mutation.
PC14586 granted Fast Track designation by the U.S. FDA.
Deepika Jalota, Pharm. D. was appointed to Chief Regulatory and Quality Officer.
Scientific Advisory Board was expanded with appointment of Guillermina (Gigi) Lozano, Ph.D.
PMV Pharma
PMV Pharma
Forward Guidance
The company did not provide specific forward guidance in this report.